Saved in this browser. Sign in to sync across devices.
Understanding the labels: Centanafadine has an FDA-approved ADHD indication. Ecopipam and the other medication trials described here remain investigational for their studied uses. ERP and CBIT are established behavioral approaches, but a specific new program or format requires its own evidence.
Jump to the condition
Autism
Cariprazine for irritability: encouraging short-term results, not an autism approval
Read the evidence and clinical questions →
ADHD
Centanafadine (Simtriyo): an approved option with substantial safety considerations
Read the evidence and clinical questions →
Depression
Intranasal mebufotenin: an experimental depression study, not an available treatment
Read the evidence and clinical questions →
Anxiety and panic
Digital CBT alongside panic medication: useful signal from a small study
Read the evidence and clinical questions →
OCD
Four-day intensive ERP performed better than unguided online CBT
Read the evidence and clinical questions →
Tourette syndrome
Ecopipam under review: a possible future option, not an approval
Read the evidence and clinical questions →
AUTISM · RESEARCH OR DECISION October 22, 2026
Cariprazine for irritability: encouraging short-term results, not an autism approval
What happened: In an eight-week trial in autistic children ages 5–17, 68.9% of children receiving cariprazine versus 38.0% receiving placebo were judged much or very much improved on a clinician-rated irritability measure.
Limits and safety: The medication is not FDA-approved for autism-related irritability; it does not treat autism itself. The short trial cannot establish long-term pediatric safety. Sleepiness and headache were reported. Outcomes should be weighed against communication, sensory, pain, sleep and environmental needs.
Question to bring to the care team
What is causing the distress, what is the child's own goal, and what established supports and safety monitoring are appropriate?
Original evidence: Findling and colleagues — original randomized trial ↗
ADHD · RESEARCH OR DECISION July 24, 2026
Centanafadine (Simtriyo): an approved option with substantial safety considerations
What happened: FDA approved centanafadine for ADHD in adults and children ages six and older weighing at least 20 kg. It is a central nervous system stimulant with a different reuptake profile from many familiar ADHD drugs.
Limits and safety: FDA labeling includes boxed warnings for pediatric suicidal ideation or behavior and for abuse, misuse and addiction; it also warns about tics or Tourette worsening and cardiovascular, psychiatric and growth effects. Approval is not evidence of superiority. At labeling, commercial release awaited scheduling; check current availability.
Question to bring to the care team
How do age, co-occurring tics or mood concerns, other medicines, nonmedication support and monitoring influence the options?
Original evidence: FDA — Simtriyo prescribing information ↗
DEPRESSION · RESEARCH OR DECISION October 26, 2026
Intranasal mebufotenin: an experimental depression study, not an available treatment
What happened: In a mid-stage study of adults with treatment-resistant major depression, the 12-mg group had a 34% day-29 response rate and an 8-mg group had 35%, versus 12% with a low-dose comparator. The 12-mg arm had a larger average depression-score improvement.
Limits and safety: The psychoactive experience complicated blinding, and low-dose comparison is not the same as a fully inactive placebo. Larger phase 3 trials and longer safety follow-up are needed. This is not approved treatment or a basis for self-administration.
Question to bring to the care team
Which established treatments have been tried adequately, and which specialist options or structured follow-up remain?
Original evidence: JAMA — original randomized clinical trial ↗
ANXIETY AND PANIC · RESEARCH OR DECISION October 5, 2026
Digital CBT alongside panic medication: useful signal from a small study
What happened: In adults receiving medication care for acute panic disorder, 17/32 using an accompanying prescription digital CBT program achieved a substantial symptom reduction, compared with 5/29 receiving medication without the app.
Limits and safety: A small, short trial of one particular product is not evidence that all mental-health apps work or that apps replace clinician-led treatment. Privacy, safety escalation, long-term follow-up and accessibility also matter.
Question to bring to the care team
Is the proposed digital tool clinically evaluated for the person's precise condition, and how does a professional monitor progress?
Original evidence: Journal of Medical Internet Research — original clinical trial ↗
OCD · RESEARCH OR DECISION October 19, 2026
Four-day intensive ERP performed better than unguided online CBT
What happened: At three months, 35 of 57 assessed participants in a concentrated exposure and response prevention program met response criteria, compared with 11 of 44 in eight weeks of unguided internet CBT.
Limits and safety: ERP is already an evidence-based OCD therapy. This result supports researching an intensive format but does not show it is superior to therapist-guided weekly ERP, suitable for every person, or effective without appropriately trained clinical support.
Question to bring to the care team
Does the clinician specialize in OCD-specific ERP, and what session pace and accessibility accommodations fit the person?
Original evidence: JAMA Network Open — original randomized clinical trial ↗
TOURETTE SYNDROME · RESEARCH OR DECISION May 26 and August 19, 2026
Ecopipam under review: a possible future option, not an approval
What happened: After an initial open-label treatment phase, 90 pediatric participants who had responded entered a randomized comparison. Continuing ecopipam reduced the hazard of tic relapse compared with switching to placebo (hazard ratio 0.47). In August the manufacturer announced FDA priority review with an anticipated 2027 decision.
Limits and safety: The result concerns selected initial responders—not every child with Tourette syndrome. Ecopipam is investigational as of October 26, 2026; regulatory approval is uncertain. CBIT remains an established behavioral therapy for troublesome tics.
Question to bring to the care team
Do tics cause pain, interference or distress, and is CBIT available? Which co-occurring ADHD, OCD or anxiety needs matter most?
Original evidence: JAMA Neurology — phase 3 randomized clinical trial ↗
How to use a research headline without rushing treatment
Ask whether the findings apply to the same age group, diagnosis, symptom and care setting. A drug approval means a regulated indication—not that it is right for everyone. An observational association, company announcement or small trial alone cannot establish personal benefit. Seek individualized medical guidance before making any treatment change.
Research matters, but so do practical accommodations, goals the person chooses, school and workplace access, respite and relationships. You can organize next steps in our everyday support plan or prepare a concise appointment guide.
Editorial method and further context
These are selected developments, not a systematic review or a ranked list of treatments. Some milestones occurred in May, July and August and are dated accordingly; they are included for their continuing relevance rather than presented as new October approvals.
For the sensory-support trial already covered on NeuroCoach, read the October 6 autism occupational therapy study explainer. For established behavioral treatment context, see IOCDF guidance on ERP and CDC guidance on CBIT.
Original sources checked October 26, 2026. Educational editorial draft. Independent clinical review pending. No article is individualized advice, an endorsement, a prescription or emergency support.